Literature DB >> 28349204

Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol.

Xavier León1,2, Cristina Valero3, Carlota Rovira1, Camilo Rodriguez1, Montserrat López1, Jacinto García-Lorenzo1, Miquel Quer1.   

Abstract

The aim of the study is to analyze the relationship between the degree of response to induction chemotherapy and the disease control in patients with locally advanced laryngeal carcinomas candidates to total laryngectomy. This retrospective study includes 389 patients with T3-T4 laryngeal tumors candidates to total laryngectomy, diagnosed between 1985 and 2013, treated with induction chemotherapy in an organ preservation protocol. Five-year local recurrence-free survival for patients receiving conservative treatment with radiotherapy after a complete response to induction chemotherapy was 75.4%; for patients with partial response greater than 50%, it was 62.0%; and for patients with the absence of response, it was 32.7%. There were significant differences in local recurrence-free survival and laryngeal dysfunction-free survival according to the response to induction chemotherapy (P = 0.0001) at the expense of patients with absence of response to induction chemotherapy. Patients with partial response greater than 50% treated with radiotherapy had a tendency to have worse local recurrence-free survival and laryngeal dysfunction-free survival than patients with complete response, but the differences did not reach statistical significance. Patients with the absence of response after induction chemotherapy had significant differences in disease-specific survival according to the second treatment: for patients treated with surgery it was 70.2%, whereas for patients treated with radiotherapy, it was 28.2% (P = 0.0001). In patients with the absence of response to induction chemotherapy, conservative treatment with radiotherapy implies a significant decrease in survival.

Entities:  

Keywords:  Advanced laryngeal carcinoma; Induction chemotherapy; Organ preservation protocol; Radiotherapy; Total laryngectomy

Mesh:

Year:  2017        PMID: 28349204     DOI: 10.1007/s00405-017-4548-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  14 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

2.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

Authors:  Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

3.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

Authors:  J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud
Journal:  J Natl Cancer Inst       Date:  1996-07-03       Impact factor: 13.506

4.  Randomized trial of induction chemotherapy in larynx carcinoma.

Authors:  J M Richard; H Sancho-Garnier; J J Pessey; B Luboinski; J L Lefebvre; D Dehesdin; M Stromboni-Luboinski; C Hill
Journal:  Oral Oncol       Date:  1998-05       Impact factor: 5.337

5.  Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy.

Authors:  Philippe Gorphe; Margarida Matias; Pierre Blanchard; Caroline Even; Charles Ferte; Yungan Tao; Stéphane Temam; François Bidault; François Janot
Journal:  Laryngoscope       Date:  2016-11-26       Impact factor: 3.325

6.  Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.

Authors:  Margarita Majem; Ricard Mesia; Manel Mañós; Joaquin Gomez; Ramon Galiana; Felipe Cardenal; Amparo Juan; Ana Montes; Francisco Javier Perez; Julio Nogues; Josep Ramon Germa Llluch
Journal:  Laryngoscope       Date:  2006-09       Impact factor: 3.325

7.  Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.

Authors:  Susan Urba; Gregory Wolf; Avraham Eisbruch; Francis Worden; Julia Lee; Carol Bradford; Theodoros Teknos; Douglas Chepeha; Mark Prince; Norman Hogikyan; Jeremy Taylor
Journal:  J Clin Oncol       Date:  2005-12-27       Impact factor: 44.544

8.  Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Authors:  J L Lefebvre; F Rolland; M Tesselaar; E Bardet; C R Leemans; L Geoffrois; P Hupperets; L Barzan; D de Raucourt; D Chevalier; L Licitra; F Lunghi; R Stupp; D Lacombe; J Bogaerts; J C Horiot; J Bernier; J B Vermorken
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

9.  Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

10.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Authors:  Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more
  1 in total

1.  A Study of Peripheral Blood Parameters to Predict Response to Induction Chemotherapy and Overall Survival in Advanced Laryngeal Squamous Cell Carcinoma.

Authors:  Jiaqi Xu; Yifan Yang; Qi Zhong; Lizhen Hou; Hongzhi Ma; Yang Zhang; Ling Feng; Shizhi He; Meng Lian; Jugao Fang; Ru Wang
Journal:  Curr Oncol       Date:  2022-09-09       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.